EUVIMEDSkopri EUVIMED
Crossref

Cost‐effectiveness analysis of dyevert™ Power XT in patients with chronic kidney disease undergoing percutaneous coronary intervention procedures in Spain

Jose R López-Mínguez iD, A L Martín de Francisco, M J Soler, Felipe Hernández iD, Raul Moreno iD, Eduardo Pinar, A Sampedro, M Mareque iD, I Oyagüez

Catheterization and Cardiovascular Interventions · 2023

DOI: 10.1002/ccd.30744 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2023. Written by Jose R López-Mínguez and 8 co-authors. Institution: Sección de Hemodinámica y Cardiología Intervencionista, Hospital Universitario de Badajoz, Badajoz, España. Major MEDLINE topics: Percutaneous Coronary Intervention, Renal Insufficiency, Chronic. Cited 1 times so far (Crossref); 39 references. Funded by: GE Healthcare Spain.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

To assess the efficiency of Dyevert™ Power XT compared to the standard clinical practice when used for percutaneous coronary interventions (PCI).

Methods

A Markov model was developed to estimate, over 3‐month cycles and a lifetime time horizon, the cumulative costs and health outcomes (life years gained [LYG] and quality‐adjusted life years [QALY]) in a hypothetical cohort of 1,000 patients with chronic kidney disease (CKD) 3b‐4 and an average age of 72 years. The incidence of contrast‐induced acute kidney injury for these patients is 18.89% in routine practice and 7.78% with Dyevert. QALYs were estimated by applying utilities by health state. Transitions between states and utilities were obtained from the literature. Overall all‐cause and state‐specific mortality were considered. The total cost (€2,022) estimated with the National Health System perspective included cost of the procedure and of CKD management. The parameters were validated by a panel of experts. A discount rate (3% per year) was applied to costs and outcomes.

Results

The use of Dyevert yielded more health benefits (34.60 LYG and 5.69 QALYs) compared to the current standard practice (33.11 LYG and 5.38 QALYs). Lifetime cost accumulated at the end of the simulation resulted €30,211/patient with Dyevert and €33,895/patient with current standard clinical practice.

Conclusions

The use of Dyevert™ Power XT resulted dominant option, due to its higher effectiveness and lower cost as compared to standard clinical practice and, therefore, a preferred option in patients with CKD stages 3b‐4 undergoing PCI in Spain.

Subjects

MeSH terms (MEDLINE)

Percutaneous Coronary InterventionRenal Insufficiency, ChronicHumansAgedCost-Effectiveness AnalysisSpainCost-Benefit AnalysisTreatment OutcomeQuality-Adjusted Life Years

Author keywords

Dyevert™ Power XTSpainchronic kidney diseasecost-effectivenesspercutaneous coronary interventions

Authors and institutions

  • Sección de Hemodinámica y Cardiología Intervencionista, Hospital Universitario de Badajoz, Badajoz, España.
  • Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, España.
  • Servicio de Nefrología, Hospital Universitari Vall d'Hebron, Barcelona, España.
  • Unidad de Hemodinámica y Cardiología Intervencionista, Clínica Universidad de Navarra, Madrid, España.
  • Unidad de Cardiología Intervencionista, Hospital Universitario La Paz, Madrid, España.
  • Departamento de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, España.

ORCID profiles: Jose R López-Mínguez, Felipe Hernández, Raul Moreno, M Mareque

Funding

  • GE Healthcare Spain

Cite

APA

López-Mínguez, J. R., Martín de Francisco, A. L., Soler, M. J., Hernández, F., Moreno, R., Pinar, E., Sampedro, A., Mareque, M., & Oyagüez, I. (2023). Cost‐effectiveness analysis of dyevert™ Power XT in patients with chronic kidney disease undergoing percutaneous coronary intervention procedures in Spain. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30744

Vancouver

López-Mínguez JR, Martín de Francisco AL, Soler MJ, Hernández F, Moreno R, Pinar E, et al. Cost‐effectiveness analysis of dyevert™ Power XT in patients with chronic kidney disease undergoing percutaneous coronary intervention procedures in Spain. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30744

BibTeX
@article{LpezMnguez2023,
  author = {López-Mínguez, Jose R and Martín de Francisco, A L and Soler, M J and Hernández, Felipe and Moreno, Raul and Pinar, Eduardo and Sampedro, A and Mareque, M and Oyagüez, I},
  title = {Cost‐effectiveness analysis of dyevert™ Power XT in patients with chronic kidney disease undergoing percutaneous coronary intervention procedures in Spain},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2023},
  doi = {10.1002/ccd.30744}
}
Start for free →